News

euSEND brings together universities, pharma firms, other international research organizations and product development partnerships to encourage development of solutions for neglected tropical diseases. The Dutch initiative builds, amongst

The renal study evaluated the safety and efficacy of Onglyza in patients with moderate to severe renal impairment or end-stage renal disease (ESRD). The 12-week data revealed that

The DSMB concluded that the studies may continue without protocol modification, and that no other formal meetings of the DSMB are needed. The DSMB reviewed safety data from

The approval includes two additional Agilent Microarray scanners and two Agilent Bioanalyzers, increasing aboratory capacity to handle the increasing number of MammaPrint, TargetPrint and BluePrint test requests. The

Votrient is a targeted oral treatment, which is an effective first-line treatment for advanced renal cell carcinoma (as acknowledged by NICE) since it slows down progression of the

The last patient has been treated with the company’s proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin at University College Hospital (UCH) in London. Principal

The report is based on a US survey of 100 rheumatologists and 20 MCO pharmacy directors. The report reveals that the surveyed rheumatologists expect a significant reduction in

In the Phase 2 portion of the trial, the company will compare treatment with IPI-926 in combination with gemcitabine to treatment with placebo and gemcitabine. The primary endpoint

The idea is to expedite the execution of Elan‘s clinical programs on a global scale keeping in mind the advancement, progression and execution of Elan’s development portfolio. PPD